In line with this, GSK3β has been found to be overactivated in muscles of the DM1 mouse model HSALR prior to the onset of muscle wasting, and GSK3β blockers improved skeletal muscle strength and reduced myotonia in this mouse model, suggesting that these inhibitors could have a beneficial effect on the treatment of DM1 by alleviating muscle wasting (Jones et al., 2012). This evidence concerns the gene GSK3B and myotonic dystrophy type 1.